Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 1
5(71.4%)
Phase 2
2(28.6%)
7Total
Phase 1(5)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07037901Phase 2Recruiting

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Role: lead

NCT06060977Phase 1Completed

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants

Role: lead

NCT05984784Phase 1Terminated

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)

Role: lead

NCT06304740Phase 1Terminated

Safety and Pharmacokinetics of Subcutaneous Dose of IMG-007 in Healthy Participants

Role: lead

NCT05349097Phase 1Completed

Study to Evaluate IMG-004 in Healthy Participants

Role: lead

NCT04795141Phase 2Terminated

ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis

Role: lead

NCT05353972Phase 1Completed

Evaluate IMG-007 in Healthy Participants

Role: lead

All 7 trials loaded